142 related articles for article (PubMed ID: 29253386)
1. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study.
Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY
Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
[TBL] [Abstract][Full Text] [Related]
6. Reducing overdose deaths among persons with opioid use disorder in connecticut.
Scheidell JD; Townsend TN; Zhou Q; Manandhar-Sasaki P; Rodriguez-Santana R; Jenkins M; Buchelli M; Charles DL; Frechette JM; Su JI; Braithwaite RS
Harm Reduct J; 2024 May; 21(1):103. PubMed ID: 38807226
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016.
Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON
Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902
[TBL] [Abstract][Full Text] [Related]
8. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
[TBL] [Abstract][Full Text] [Related]
9. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.
Price JT; Wheeler SB; Stranix-Chibanda L; Hosek SG; Watts DH; Siberry GK; Spiegel HM; Stringer JS; Chi BH
J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S145-53. PubMed ID: 27355502
[TBL] [Abstract][Full Text] [Related]
12. The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward.
Case KK; Gomez GB; Hallett TB
J Int AIDS Soc; 2019 Sep; 22(9):e25390. PubMed ID: 31538407
[TBL] [Abstract][Full Text] [Related]
13. A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease.
Kazemian P; Costantini S; Neilan AM; Resch SC; Walensky RP; Weinstein MC; Freedberg KA
J Biomed Inform; 2020 Jul; 107():103475. PubMed ID: 32526280
[TBL] [Abstract][Full Text] [Related]
14. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.
Walensky RP; Jacobsen MM; Bekker LG; Parker RA; Wood R; Resch SC; Horstman NK; Freedberg KA; Paltiel AD
J Infect Dis; 2016 May; 213(10):1523-31. PubMed ID: 26681778
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-making.
Chen A; Dowdy DW
PLoS One; 2014; 9(10):e108742. PubMed ID: 25285793
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of the effect of needle and syringe programs on skin, soft tissue, and vascular infections in people who inject drugs: a microsimulation modelling approach.
Lim J; El-Sheikh M; Buckeridge DL; Panagiotoglou D
Harm Reduct J; 2024 Jun; 21(1):126. PubMed ID: 38943164
[TBL] [Abstract][Full Text] [Related]
17. Commentary: the value of PrEP for people who inject drugs.
Coleman RL; McLean S
J Int AIDS Soc; 2016; 19(7(Suppl 6)):21112. PubMed ID: 27760686
[TBL] [Abstract][Full Text] [Related]
18. An economic evaluation of community pharmacy-dispensed naloxone in Canada.
Cid A; Mahajan N; Wong WWL; Beazely M; Grindrod KA
Can Pharm J (Ott); 2024; 157(2):84-94. PubMed ID: 38463179
[TBL] [Abstract][Full Text] [Related]
19. Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis.
Popping S; Nichols BE; Appelman B; Biemond JJ; Vergouwe M; Rosendaal FR; van der Valk M; de Bree GJ; Wiersinga WJ; Birnie E;
JAMA Netw Open; 2023 Jul; 6(7):e2321985. PubMed ID: 37410460
[TBL] [Abstract][Full Text] [Related]
20. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study.
Borquez A; Beletsky L; Nosyk B; Strathdee SA; Madrazo A; Abramovitz D; Rafful C; Morales M; Cepeda J; Panagiotoglou D; Krebs E; Vickerman P; Claude Boily M; Thomson N; Martin NK
Lancet Public Health; 2018 Sep; 3(9):e429-e437. PubMed ID: 30122559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
